Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Down 84.8% in July

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totaling 17,399 shares, a decrease of 84.8% from the June 30th total of 114,234 shares. Based on an average trading volume of 41,300 shares, the short-interest ratio is currently 0.4 days. Approximately 1.2% of the shares of the stock are sold short.

Institutional Trading of Global X Genomics & Biotechnology ETF

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC grew its position in Global X Genomics & Biotechnology ETF by 7.7% during the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after buying an additional 10,308 shares during the period. Bank of America Corp DE lifted its position in shares of Global X Genomics & Biotechnology ETF by 67.8% during the 1st quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock valued at $5,240,000 after acquiring an additional 48,394 shares during the period. Sei Investments Co. boosted its stake in shares of Global X Genomics & Biotechnology ETF by 110.4% during the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after acquiring an additional 12,105 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Global X Genomics & Biotechnology ETF by 30.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after acquiring an additional 4,615 shares in the last quarter. Finally, U.S. Capital Wealth Advisors LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the 4th quarter worth approximately $575,000. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Stock Performance

Global X Genomics & Biotechnology ETF stock traded up $0.03 during midday trading on Monday, reaching $54.02. The company’s stock had a trading volume of 6,602 shares, compared to its average volume of 15,423. Global X Genomics & Biotechnology ETF has a fifty-two week low of $34.04 and a fifty-two week high of $59.48. The stock’s 50 day simple moving average is $52.16 and its 200 day simple moving average is $48.20. The firm has a market capitalization of $78.87 million, a PE ratio of -23.09 and a beta of 1.16.

Global X Genomics & Biotechnology ETF Announces Dividend

The business also recently declared a dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 29th were issued a $0.0579 dividend. The ex-dividend date was Monday, June 29th. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is currently -27.35%.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.